Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis by unknown
RESEARCH ARTICLE Open Access
Effectiveness of regionally-specific
immunotherapy for the management
of canine atopic dermatitis
Jon D. Plant1* and Moni B. Neradilek2
Abstract
Background: Canine atopic dermatitis is a common pruritic skin disease often treated with allergen
immunotherapy (AIT). AIT in dogs traditionally begins with attempting to identify clinically relevant environmental
allergens. Current allergen testing methodologies and immunotherapy techniques in dogs are not standardized.
Immunotherapy with a mixture of allergenic extracts selected based on regional aerobiology rather than
intradermal tests or serum IgE assays has been described. The objective of this study was to evaluate the
effectiveness of regionally-specific immunotherapy in dogs with atopic dermatitis. The medical records of a
veterinary dermatology referral clinic were searched for dogs with atopic dermatitis that began regionally-specific
subcutaneous immunotherapy from June, 2010 to May, 2013. An overall assessment of treatment effectiveness
(excellent, good, fair, or poor) was assigned based upon changes in pruritus severity, lesion severity, and the
reduction in concurrent medication(s) during a follow-up period of at least 270 days. Baseline characteristics that
might predict treatment success were analyzed with the Spearman’s correlation and the Kruskal-Wallis tests.
Results: Of the 286 dogs that began regionally-specific immunotherapy (RESPIT) during a 3 year period, 103 met
the inclusion criteria. The overall response to RESPIT was classified as excellent in 19%, good in 38%, fair in 25%,
and poor in 18% of dogs. The response classification correlated significantly with a reduction in pruritus severity
(r = 0.72, p < 0.001) and lesion severity (r = 0.54, p < 0.001), but not with the dogs’ baseline characteristics. Adverse
reactions were reported in 7/286 (2.4%) of treated dogs.
Conclusions: Under the conditions of this study, RESPIT was safe and effective for the treatment of atopic
dermatitis in dogs.
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Background
Canine atopic dermatitis (AD) is a common inflammatory
and pruritic skin disease that is frequently associated with
sensitization to environmental allergens [1]. Affected dogs
often exhibit pruritus of the face, pinnae, feet, axillae, and
inguinal region [2]. Secondary otitis externa, staphylococ-
cal pyoderma and Malassezia dermatitis frequently de-
velop in atopic dogs.
Canine AD often requires long-term management
and therapy [1]. There is substantial evidence to support
the use of glucocorticoids, cyclosporine, oclacitinib, and
allergen immunotherapy (AIT) for canine AD [3]. With
AIT, dogs are given allergenic extracts in order to
minimize flares upon subsequent natural exposure [4].
The mechanism of action of AIT is not well defined in
dogs, but may include the production of blocking IgG
antibodies, a shift in the cytokine balance from a pre-
dominantly T-helper (Th) 2 to a Th1 cell profile, and a
regulatory T-cell response [5, 6]. Therapeutic allergens
are identified through a combination of aerobiology,
intradermal test (IDT) findings, serum allergen-specific
IgE assays (SIA), and clinical history [2]. Allergenic ex-
tracts are administered either by subcutaneous injec-
tion or via application to the oral mucosa [3].
Allergen immunotherapy prescriptions are customized
for each dog. An optimal allergenic extract mixture would
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contain only allergens that elicit clinical signs upon
natural exposure. However, customizing an allergenic ex-
tract involves multiple subjective variables. Veterinarians
choose which allergens to test for, whether to test with
IDT or SIA, which laboratory’s SIA to use, how to inter-
pret borderline reactions, which positive reactions are
deemed clinically relevant, what dose of each allergen to
include in the ASIT prescription, and by what schedule
and route it will be administered. These variables are not
trivial. Within a geographic region, the allergens veterinary
dermatologists evaluate with IDT vary substantially [7], as
do the allergens assayed by different laboratories offering
SIA [8]. The agreement between IDT and SIA findings is
often poor [2]. False positive and false negative results
occur with both testing methods [1]. Recently, Plant et al.
found poor agreement between four SIAs, indicating that
the choice of laboratories is likely to influence treatment
recommendations [9]. Once allergens are selected for in-
clusion, the optimal dose of each is unknown in veterinary
medicine. Allergen immunotherapy may, therefore, be
considered a heterogeneous therapy.
Although subject to the variables described above, AIT
has been found to be effective for the management of
canine AD in one placebo-controlled and multiple retro-
spective studies [5]. Results from these studies are diffi-
cult to compare directly because they report different
outcome measures, but those that defined effectiveness
as a greater than 50% reduction in pruritus and lesion
severity found AIT to be effective in 52–77% of dogs [5].
In most of these studies, the response to AIT was inde-
pendent of the testing method, the age of onset of AD,
the age at which AIT was begun, and the duration of
disease prior to AIT. Mixed findings have been reported
concerning the correlation of treatment success with
breed, gender, and the seasonality of signs [5].
An alternative to AIT is RESPIT, allergenic extract
mixtures that are formulated based on a dog’s geo-
graphic location rather than individual allergy test find-
ings. Reports on the use of non-specific AIT mixtures in
dogs or humans are limited [10–12]. The aim of this
study was to evaluate the effectiveness of subcutaneous
RESPIT for the treatment of atopic dermatitis in 103
dogs that began therapy during a 3-year period at a vet-
erinary dermatology clinic in the northwestern United
States.
Methods
The electronic medical records (Vetport, Vetport, LLC,
Milford, OH, USA) of a veterinary dermatology clinic were
searched for dogs with AD for which RESPIT (RESPIT®
Injectable Region 1, Respit, LLC, Lake Oswego, OR, USA)
was prescribed on the same date as an initial examination
between June 1, 2010 and May 31, 2013. The diagnosis of
AD was made based on identifying characteristic clinical
features and ruling out alternative diagnoses [13].
The following history and examination findings from
the initial encounter on day 0 (D0) were exported to a
spreadsheet: patient identification, date of birth, gender,
breed, weight, encounter date, pruritus visual analogue
scale (PVAS) [14], seasonality of signs, current medica-
tions, and lesion severity. Lesion severity was recorded
with an ad hoc canine lesion severity index (LSI) with a
range from 0 to 1000 (the product of lesion severity
graded from 0 to 10 and estimated percent body area af-
fected). Dogs without a D0 PVAS entry were excluded
from analysis. The records of the remaining dogs were
reviewed to identify those that returned for an examin-
ation after receiving RESPIT for at least 270 days. Nine
to twelve months is often the duration of therapy recom-
mended to evaluate the response to AIT in dogs [15,
16]. The date of the first examination following 270 days
of RESPIT therapy (designated D270+) was recorded
and the following data were further extracted from the
medical records: D270+ PVAS, D270+ LSI, D270+ con-
current medication(s), and adverse reactions suspected
by the pet owner. The last date that RESPIT was dis-
pensed before July 15, 2015 was also recorded.
On the basis of the changes in the dogs’ PVAS, LSI, and
those concomitant systemic medications with substantial
evidence of efficacy (glucocorticoids, cyclosporine, or ocla-
citinib) between D0 and D270+, an overall assessment
score was assigned by the primary investigator as follows:
1 (poor) = no clinical change or a deterioration, 2 (fair) =
improvement, but concurrent medications could not be
substantially decreased, 3 (good) = greater than 50% im-
provement in clinical signs and reduction in medications,
4 (excellent) = complete remission without concurrent
medications [17]. The percentages of dogs with D270+
PVAS in the normal (<2.0) and mild (2.0–3.5) ranges were
determined.
All statistical analyses were carried out in the statistical
software R: A Language and Environment for Statistical
Computing (R Foundation for Statistical Computing,
Vienna, Austria) version 3.1.3. Continuous and categorical
characteristics were analyzed with Spearman’s correlation
and the Kruskal-Wallis test, respectively. A P-value of
<0.05 was considered statistically significant. Trends in
bivariate relationships were highlighted by local regression
trend lines [18].
Results
During a 3 year period, 286 dogs with AD began
RESPIT on the day of an initial examination during
which the pruritus severity was recorded. Of these
dogs,103 (36%) returned for an examination after
270 days while still receiving RESPIT, thereby meeting
the inclusion criteria. Most commonly, dogs were
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excluded due to poor compliance. Eighty-five dogs re-
ceived only the initial prescription of RESPIT, an insuffi-
cient volume to last 270 days. Three of these dogs
transitioned to an oromucosal formulation of RESPIT.
Fifty-five dogs had their prescriptions renewed for the last
time before day 200 and likely did not receive a volume
sufficient to reach D270+. These 55 dogs were not exam-
ined after D270 while receiving subcutaneous RESPIT.
Two of these dogs also transitioned to the oromucosal for-
mulation of RESPIT. D270+ examinations while receiving
RESPIT were not performed for 39 dogs that did have
RESPIT prescriptions renewed after day 200. Four add-
itional dogs had lengthy (7 month to 4 year) lapses in ther-
apy before the D270+ examinations. The D0 baseline
characteristics (age, weight, gender, seasonality of signs,
PVAS, and LSI) of the included (n = 103) and excluded
(n = 183) dogs were not significantly different (p > 0.05).
The overall response to RESPIT was scored as excellent
in 19%, good in 38%, fair in 25%, and poor in 18% of dogs.
The percentages of dogs with normal or mild pruritus
at D270+ were 20 and 25%, respectively. The mean
duration of therapy evaluated was 424 days (median
365, range 273–1735 days). D0 age (r = 0.06, p = 0.5),
weight (r = −0.03, p = 0.7), gender (p = 0.2), pruritus se-
verity (r = 0.09, p = 0.4), lesion severity (r = 0.10, p =
0.3), seasonal history (p = 0.2), and the calendar month
of the D270+ examination (p = 0.8, Fig. 1) did not cor-
relate significantly with the response classification. The
number of dogs assigned to each response classifica-
tion per 30-day period following D270+ is depicted in
Fig. 2. Ninety percent of dogs scored as excellent and
33% of dogs scored as good were not receiving anti-
pruritic medications at the time of the D270+ examin-
ation (Table 1). One dog scored as excellent was re-
ceiving occasional oral diphenhydramine and a second
infrequent topical fluocinonide cream.
The response classification at D270+ significantly corre-
lated with a reduction in pruritus severity (Fig. 3, r = 0.72,
p < 0.001), a reduction in lesion severity (Fig. 4, r = 0.54, p <
0.001), the duration of therapy to D270+ (r= 0.24, p = 0.02)
and the total duration of therapy as of the date of the data
retrieval (r = 0.40, p < 0.001).
No adverse reactions to RESPIT were reported in the
103 evaluable dogs meeting the inclusion criteria. Seven
of 286 dogs initially screened (2.4%) were suspected by
pet owners to have experienced adverse reactions to
RESPIT, including three with increased pruritus, and
one each with vomiting, blepharitis, restlessness, or urti-
caria. In 5/7 dogs the dose was decreased and RESPIT
was continued. In one dog with increased pruritus dur-
ing the induction phase, RESPIT was temporarily dis-
continued then resumed 1 month later following the
induction schedule up to a lower maintenance dose. In
the dog that reportedly developed hives after two injec-
tions, RESPIT was discontinued by the owner and the
dog was lost to follow up.
Discussion
In this study, 59/103 dogs (57%) had good or excellent
responses to RESPIT. Similar rates have been reported
in studies evaluating AIT effectiveness [5, 15–17, 19,
20]. Therapeutic extracts are likely to be imperfectly
matched with dogs’ actual sensitivity with both AIT and
RESPIT, perhaps accounting for the similarity in re-
sponse rates.
The efficacy of immunotherapy using uniform allergen
mixtures has been evaluated in two randomized con-
trolled trials in atopic dogs, both reported only in ab-
stract form with limited details or analysis [10, 11]. In a
12-month study of 78 dogs, Garfield found a 76% good
to excellent response (>51% resolution of pruritus) to a
uniform mixture of 32 aqueous allergens [10]. This was
not significantly different from the response of those
dogs that received either of two doses of AIT based on
IDT findings. In contrast are the findings of an 8-month
trial of 30 dogs in which a uniform mixture of four
alum-precipitated allergens (house dust, dog dander,
human dander, and grass mix) was compared to AIT.
Fig. 1 Effectiveness of regionally-specific immunotherapy by calendar
month of follow-up examination in 103 dogs with atopic dermatitis
Fig. 2 Effectiveness of regionally-specific immunotherapy by duration
of treatment in 97 atopic dogs. Dogs with follow-up examinations
beyond 21 months (2 classified as excellent, 2 as good, and 2 as fair)
are not depicted
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The median improvement in clinical scores (pruritus
and lesion severity) was 70% in the AIT group and 18%
in the group that received the uniform mixture of aller-
gens [11]. The discrepancy in response rates between
the latter study versus those of Garfield and the present
study may reflect differences in the number or type of
allergens in the uniform mixtures and their formulations
(alum-precipitated vs. aqueous).
Beneficial effects of immunotherapy with imperfectly
matched or unrelated allergens have also been reported in
cats and humans [12, 21, 22]. In a feline asthma model,
eosinophilic airway inflammation responded to AIT with
allergens matched to experimental sensitization, but also
to immunotherapy with imperfectly matched or unrelated
allergens [21]. Cats dually sensitized to both Bermuda
grass allergen and house dust mite given AIT to either
allergen displayed decreased eosinophilic airway inflam-
mation and higher levels of CD4+ CD25+ FoxP3+ Treg
cells compared to placebo-treated cats. Differences
were found in the immunological responses of cats
given sensitivity-matched allergens versus those given
unrelated allergens. Cats monosenesitized to Bermuda
grass allergen displayed evidence of lymphocyte hypo-
proliferation during immunotherapy with Bermuda
grass allergen, whereas Bermuda grass sensitized cats
displayed lymphocyte hyperproliferation with house
dust mite immunotherapy. The authors concluded that
sensitizing allergens and those used in AIT need not be
identically matched in order to provide a clinical bene-
fit. Analogous findings have been reported in humans
sensitive to both birch and grass pollen [22]. Sublingual
immunotherapy with either birch or grass pollen led to
clinical improvement and lower nasal eosinophil counts
during both pollen seasons, although the improvement
was greater when both were given.
Whereas perfectly matching an atopic dog’s clinical
sensitivity is the objective of AIT, the mechanism of ac-
tion of RESPIT may be both allergen-specific and non-
specific. Phylogenetically related allergens frequently
cross react on IDT in atopic dogs [23]. About 30 major
groups of cross-reactive botanical proteins have been
identified [24]. The RESPIT extract used in this study
contained 20 allergens representing a spectrum of bo-
tanically related allergen groups and house dust mites.
Table 1 Number of dogs per response classification receiving











None 4 (22%) 6 (23%) 13 (33%) 18 (90%)
Oral glucocorticoid 7 (39%) 10 (38%) 17 (44%) 0 (0%)
Cyclosporine 4 (22%) 7 (27%) 7 (18%) 0 (0%)
Oclacitinib 0 (0%) 0 (0%) 2 (5%) 0 (0%)
Antihistamine 3 (17%) 5 (19%) 1 (3%) 1 (5%)
Topical glucocorticoid,
including otic
1 (6%) 1 (4%) 0 (0%) 1 (5%)
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Fig. 3 Effectiveness of regionally-specific immunotherapy in dogs
versus change in pruritus severity. The change in the PVAS equals
the PVAS at D270+ minus the PVAS at D0. The line is a locally
weighted scatterplot smoother with the shaded area showing the

















Fig. 4 Effectiveness of regionally-specific immunotherapy in dogs
versus change in lesion severity. The change in LSI equals the LSI at
D270+ minus the LSI at D0. The line is a locally weighted scatterplot
smoother with the shaded area showing the 95% confidence interval
around the point-wise mean
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RESPIT may imperfectly match an atopic dog’s actual
sensitivities, but include some allergen-specific epitopes
as well as panallergens (e.g. profilins, polcalcins, and
non-specific lipid transfer proteins) common to distinct
allergen groups. Although panallergens are widely dis-
tributed in nature with highly conserved amino acid se-
quence regions, structures, and functions, their clinical
significance in human allergy is unclear [24, 25].
In the present study, the median duration of therapy
at the time of the D270+ evaluation was 12 months and
the majority of D270+ evaluations (74/103) occurred be-
tween 9 and 15 months after beginning RESPIT (Fig. 2).
The slight correlation between the days until D270+ and
response classification, and the moderate correlation
between the total length of therapy and response classifi-
cation at D270+ likely reflect pet owners’ higher level of
compliance when satisfied with their dogs’ response. The
calendar month during which D270+ evaluations took
place did not correlate with the response to RESPIT
(Fig. 1). Taken together, these findings suggest that the
possible confounding variable of seasonality did not ac-
count for the clinical improvement detected in this study.
Similar to a number of retrospective studies of AIT in
atopic dogs [5], these results suggest that a dog’s re-
sponse to RESPIT cannot be predicted from their age,
weight, gender, or from the seasonality of their signs.
The relatively low number of dogs of any given breed
did not allow for rigorous analysis of the possible correl-
ation of breed and response classification. Neither D0
pruritus severity nor lesion severity significantly corre-
lated with the response classification. The dataset did
not allow for precise reporting of the duration of clinical
signs prior to RESPIT therapy.
For many pet owners, pruritus is the most important
burden of canine atopic dermatitis [26]. Pruritus severity
was scored with the validated visual analog scale [10],
however, lesion severity was scored with an ad hoc scale
(LSI). The third iteration of the canine atopic dermatitis
extent and severity index, the only validated lesion sever-
ity scale available when the data collection began, was
not practical for routine use in a clinical setting [27].
Immunotherapy with irrelevant allergens could, in the-
ory, lead to the development of clinical sensitivity. This
outcome may occur with either RESPIT or AIT with im-
perfectly matched allergens. However, this study found that
the prevalence of adverse reactions to RESPIT (2.4%) was
at the low end of the wide range reported for AIT (5–50%)
[4, 5]. In a small study, immunotherapy with irrelevant al-
lergens did not lead to the development of clinical signs of
atopic dermatitis in normal dogs [28].
In children with rhinitis or asthma who are sensitive
to house dust mite, AIT may have a tolerogenic effect,
preventing the sensitization to additional allergens by
inducing a shift from a TH2 to a TH1 allergen response
[29]. Irrelevant allergens that are prescribed in either
AIT or RESPIT may also confer some degree of non-
specific allergen tolerance. This could explain, in part,
why the reported success rates of AIT are similar when
utilizing a variety of allergy testing techniques and as-
says that exhibit poor agreement with one another [9].
A limitation of this study was the open, retrospective
design, similar to most studies on the effectiveness of AIT
[5]. A placebo-controlled trial could provide a higher level
of evidence concerning the efficacy of immunotherapy,
but may suffer from a high rate of non-compliance during
a long-term study. Forty-three percent of dogs were lost
to follow up by 12 months in the prospective study of AIT
by Willemse [16]. A second limitation of our study was
that only 36% of the dogs initially identified met the inclu-
sion criteria, which required a follow-up examination after
270 days of therapy. In the current study, dogs that con-
tinued to receive RESPIT prescribed by their primary care
veterinarian but did not return for the D270+ examination
were excluded. Allowing telephone interviews for follow-
up, as have some retrospective studies of AIT [15, 20],
may have resulted in excluding fewer dogs, but would not
have allowed for consistent scoring of pruritus and lesion
severity.
Conclusion
This retrospective study suggests that subcutaneous
RESPIT is a safe and effective alternative to AIT in atopic
dogs with the advantage of avoiding the subjectivity in-
volved in allergy testing and AIT formulation.
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